CN1274387A - Hcve2糖蛋白高变区1的拟表位及其用途 - Google Patents

Hcve2糖蛋白高变区1的拟表位及其用途 Download PDF

Info

Publication number
CN1274387A
CN1274387A CN99801173A CN99801173A CN1274387A CN 1274387 A CN1274387 A CN 1274387A CN 99801173 A CN99801173 A CN 99801173A CN 99801173 A CN99801173 A CN 99801173A CN 1274387 A CN1274387 A CN 1274387A
Authority
CN
China
Prior art keywords
peptide
antibody
composition
mentioned
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99801173A
Other languages
English (en)
Chinese (zh)
Inventor
A·尼科西亚
A·拉姆
A·特拉蒙塔诺
R·科尔泰瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Publication of CN1274387A publication Critical patent/CN1274387A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN99801173A 1998-05-19 1999-05-14 Hcve2糖蛋白高变区1的拟表位及其用途 Pending CN1274387A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9810756.8 1998-05-19
GBGB9810756.8A GB9810756D0 (en) 1998-05-19 1998-05-19 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof

Publications (1)

Publication Number Publication Date
CN1274387A true CN1274387A (zh) 2000-11-22

Family

ID=10832337

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99801173A Pending CN1274387A (zh) 1998-05-19 1999-05-14 Hcve2糖蛋白高变区1的拟表位及其用途

Country Status (13)

Country Link
US (1) US7034108B1 (enExample)
EP (1) EP1002092B1 (enExample)
JP (1) JP4593780B2 (enExample)
KR (1) KR20010022026A (enExample)
CN (1) CN1274387A (enExample)
AT (1) ATE308618T1 (enExample)
AU (1) AU766610B2 (enExample)
CA (1) CA2297408C (enExample)
DE (1) DE69928064T2 (enExample)
DK (1) DK1002092T3 (enExample)
ES (1) ES2251832T3 (enExample)
GB (1) GB9810756D0 (enExample)
WO (1) WO1999060132A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305898C (zh) * 2003-08-22 2007-03-21 中国科学院上海生命科学研究院 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途
CN110078800A (zh) * 2019-04-24 2019-08-02 中国人民解放军第二军医大学 合成肽在制备防治肝炎病毒感染药物中的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
EP1290230A4 (en) * 2000-06-02 2004-10-20 Merck & Co Inc HEPATITIS C VIRUS CONJUGATE
WO2002045743A2 (en) * 2000-12-09 2002-06-13 Cambridge University Technical Services Limited Hcv vaccines
EP2172552A3 (en) 2001-10-11 2010-07-21 Merck Sharp & Dohme Corp. Recombinant nucleic acids comprising regions of AD6
DK1436397T3 (da) 2001-10-11 2010-08-09 Merck Sharp & Dohme Hepatitis C virus vaccine
JP5475279B2 (ja) 2005-06-17 2014-04-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｃ型肝炎ウイルス核酸ワクチン
CN101336110B (zh) * 2006-06-01 2011-06-01 程云 预防或治疗肝损伤的肽及其衍生物及其应用
WO2007146975A2 (en) * 2006-06-13 2007-12-21 Athenix Corporation Methods for generating genetic diversity by permutational mutagenesis
AU2007347119B2 (en) 2006-11-29 2012-02-02 BASF Agricultural Solutions Seed US LLC Improved GRG23 EPSP synthases: compositions and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
EP1421951A3 (en) 1993-05-12 2005-10-05 Chiron Corporation Conserved motif of hepatitis C virus E2/NS1 region
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
JPH11124398A (ja) * 1997-10-22 1999-05-11 Japan Energy Corp Ｃ型肝炎ウイルス由来の抗原ペプチドとそれを用いる抗体検査薬

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305898C (zh) * 2003-08-22 2007-03-21 中国科学院上海生命科学研究院 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途
CN110078800A (zh) * 2019-04-24 2019-08-02 中国人民解放军第二军医大学 合成肽在制备防治肝炎病毒感染药物中的用途

Also Published As

Publication number Publication date
ATE308618T1 (de) 2005-11-15
ES2251832T3 (es) 2006-05-01
JP2002515249A (ja) 2002-05-28
US7034108B1 (en) 2006-04-25
KR20010022026A (ko) 2001-03-15
DE69928064D1 (de) 2005-12-08
EP1002092A1 (en) 2000-05-24
EP1002092B1 (en) 2005-11-02
DE69928064T2 (de) 2006-07-20
CA2297408A1 (en) 1999-11-25
GB9810756D0 (en) 1998-07-15
AU766610B2 (en) 2003-10-16
CA2297408C (en) 2011-06-21
WO1999060132A1 (en) 1999-11-25
AU4143599A (en) 1999-12-06
JP4593780B2 (ja) 2010-12-08
DK1002092T3 (da) 2006-03-06

Similar Documents

Publication Publication Date Title
CN1179973C (zh) 含有通过肽配体连接的多个免疫原性成分的hbv核心抗原颗粒
CN1174998C (zh) 用于预防和治疗过敏的肽免疫原
CN1093881C (zh) 免疫原或诊断剂的制备及其获得免疫原或诊断试剂的方法
CN1073118C (zh) C型肝炎病毒的检测方法
CN1170593C (zh) 缩胆囊素-b/胃泌素受体的免疫原性组合物以及治疗肿瘤的方法
CN1073719A (zh) 非a和非b肝炎病毒的诊断及疫苗
CN1310626A (zh) 具有增强药物动力特性的杂合肽
CN1091138A (zh) 疫苗
CN1108030A (zh) 丙型肝炎病毒基因型的新顺序及其作为治疗和诊断试剂的用处
CN1673744A (zh) 癌症的治疗和诊断
CN1609617A (zh) 诊断与预防严重急性呼吸道综合症（sars）的组合物和方法
CN101048659A (zh) 抗前胃泌素单克隆抗体
CN1419564A (zh) 包含脑膜炎奈瑟氏球菌表面抗原NhhA的保守区域的蛋白质
CN1118474C (zh) 合成肽及包含其的疫苗
CN1136778A (zh) 与一种精子区带结合蛋白的自身抗原性抗原决定基相对应的精子抗原
CN1274387A (zh) Hcve2糖蛋白高变区1的拟表位及其用途
CN1151185A (zh) 瘟病毒株的核苷酸序列，由这些序列编码的多肽及其在诊断和预防瘟病毒感染中的应用
CN1590409A (zh) 针对sars冠状病毒n蛋白抗原的抗体及其在sars冠状病毒或者其抗原检测中的用途
CN1261896A (zh) 诊断和预防莱姆病用的组合物的表面抗原和蛋白质
CN1751122A (zh) 具有改进特性的干扰素α突变蛋白的融合蛋白
Zucchelli et al. Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross‐reactive antibody response by genetic immunization
CN1249781A (zh) 登革病毒的前m/m蛋白的表位、合成肽
CN1622828A (zh) 用于诊断和治疗用途的纯化的丙型肝炎病毒外被蛋白
CN1768078A (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
CN1856503A (zh) 来源于c型肝炎病毒的肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication